A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Fulvestrant|DRUG: GDC-0810
Sponsor: Genentech, Inc.